CD8A and neoplasm: Tumor regressions in vivo due to anti-HER2 mAb therapy also require an effective adaptive anti-tumor immune response to reach optimal therapeutic effects, and levels of CD8 and interferon-gamma have been shown to correlate with anti-HER2 treatment.